Drug Trial Radar · NCT03467425
INTREPID: Investigation of TRELEGY Effectiveness: Usual Practice Design
Last checked: Nov 19, 2026Latest source record: Sep 7, 2020 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
3,109
Actual
Start
Apr 11, 2018
Primary completion
Oct 10, 2019
Study completion Oct 10, 2019
Sponsor
- Lead sponsor
- GlaxoSmithKlineGSK (GSK)
- Sponsor type
- Industry
- First posted
- Mar 16, 2018
Design
- Study type
- Interventional
- Phase
- Phase 4
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 40 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The primary purpose of this study is to assess the effectiveness of TRELEGY ELLIPTA relative to non-ELLIPTA Multiple Inhaler Triple Therapies (MITT) for Chronic Obstructive Pulmonary Disease (COPD) control within the usual clinical practice setting. The study will be conducted once TRELEGY ELLIPTA has been approved in the countries in which the study will be conducted and is available commercially. This is a randomized, open-label, effectiveness, phase 4 study of 24 weeks' duration in COPD subjects to evaluate TRELEGY ELLIPTA (fluticasone furoate \[FF\]/vilanterol \[VI\]/umeclidinium bromide \[UMEC\]: 100 microgram \[mcg\]/62.5 mcg/25 mcg) inhalation powder taken once daily using a single ELLIPTA inhaler compared with any non-ELLIPTA MITT in the usual care setting. Effectiveness of TRELEGY ELLIPTA will be assessed by comparing proportion of COPD Assessment Test (CAT) responders at Week 24 between two treatment groups. TRELEGY and ELLIPTA are trademarks of GlaxoSmithKline (GSK) group of companies. The study will enroll approximately 3000 subjects.
Conditions
- Pulmonary Disease, Chronic Obstructive
Interventions
FF/UMEC/VIDrug
FF is a dry white powder containing 100 mcg GW685698 blended with lactose in one blister in the first strip of the DPI. UMEC/VI is a dry white powder containing 62.5 mcg of UMEC and 25 mcg of VI per blister, both blended together with lactose and magnesium stearate in the second strip of the DPI.
Inhaled CorticosteroidDrug
Inhaled Corticosteroid (ICS) as prescribed by the physician.
LAMADrug
LAMA as prescribed by the physician.
LABADrug
LABA as prescribed by the physician.
COPD rescue medicationsDrug
Rescue medications for COPD will be prescribed and obtained according to usual practice.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Number of Responders and Non-responders Based on the Chronic Obstructive Pulmonary Disease Assessment Test (CAT) at Week 24 and Number of Participants With Imputed CAT Score at Week 24Time frame: At Week 24
Locations
143 sites in 5 countries. Site status is shown where the registry gives one.
GSK Investigational Site
Berlin, Germany
GSK Investigational Site
Berlin, Germany
GSK Investigational Site
Berlin, Germany
GSK Investigational Site
Berlin, Germany
GSK Investigational Site
Berlin, Germany
GSK Investigational Site
Berlin, Germany
GSK Investigational Site
Berlin, Germany
GSK Investigational Site
Berlin, Germany
GSK Investigational Site
Berlin, Germany
GSK Investigational Site
Berlin, Germany
GSK Investigational Site
Berlin, Germany
GSK Investigational Site
Deggendorf, Germany
GSK Investigational Site
Hamburg, Germany
GSK Investigational Site
Aschaffenburg, Bavaria, Germany
GSK Investigational Site
Dachau, Bavaria, Germany
GSK Investigational Site
Garmisch-Partenirchen, Bavaria, Germany
GSK Investigational Site
Wallerfing, Bavaria, Germany
GSK Investigational Site
Cottbus, Brandenburg, Germany
GSK Investigational Site
Fürstenwalde, Brandenburg, Germany
GSK Investigational Site
Potsdam, Brandenburg, Germany
GSK Investigational Site
Potsdam, Brandenburg, Germany
GSK Investigational Site
Rüdersdorf, Brandenburg, Germany
GSK Investigational Site
Darmstadt, Hesse, Germany
GSK Investigational Site
Frankfurt am Main, Hesse, Germany
GSK Investigational Site
Frankfurt am Main, Hesse, Germany
GSK Investigational Site
Fulda, Hesse, Germany
GSK Investigational Site
Marburg, Hesse, Germany
GSK Investigational Site
Rodgau, Hesse, Germany
GSK Investigational Site
Rüsselsheim am Main, Hesse, Germany
GSK Investigational Site
Hanover, Lower Saxony, Germany
GSK Investigational Site
Hanover, Lower Saxony, Germany
GSK Investigational Site
Peine, Lower Saxony, Germany
GSK Investigational Site
Wardenburg, Lower Saxony, Germany
GSK Investigational Site
Bergisch Gladbach, North Rhine-Westphalia, Germany
GSK Investigational Site
Bonn, North Rhine-Westphalia, Germany
GSK Investigational Site
Cologne, North Rhine-Westphalia, Germany
GSK Investigational Site
Essen, North Rhine-Westphalia, Germany
GSK Investigational Site
Essen, North Rhine-Westphalia, Germany
GSK Investigational Site
Gelsenkirchen, North Rhine-Westphalia, Germany
GSK Investigational Site
Rheine, North Rhine-Westphalia, Germany
Showing 40 of 143 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.